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Background: In Israel, an average of 37 children are born each year with sepsis and another four with meningitis
as a result of Group B Streptococcal (GBS) disease. Israel currently only screens mothers with defined risk factors
(around 15% of all pregnancies) in order to identify candidates for Intrapartum Antiobiotic Prophyhlaxis (IAP) of
GBS. This paper presents a cost-utility analysis of implementing an alternative strategy, which would expand the
current protocol to one aiming to screen all pregnant women at 35–37 weeks gestation based on taking a vaginal
culture for GBS.
Methods: A spreadsheet model was built incorporating technical, epidemiological, health service costs,
demographic and economic data based primarily on Israeli sources.
Results: The intervention of universal screening (compared with the current scenario) would increase screening
costs from 580,000 NIS to 3,278,000 million NIS. In addition, the intervention would also increase penicillin costs
from 39,000 NIS to 221,000 NIS. Current culture screening of approximately 15% of mothers-to-be with high risk
factors resulted in 42 GBS births in 2008-9 (0.253/1000 births). Expanding culture screening to 85% of mothers-to-be,
will decrease the number of GBS births to 17.3 (0.104/1000 births). The initial 2.9 million NIS incremental
intervention costs are offset by decreased treatment costs of 1.9 million NIS and work productivity gains of 811,000
NIS as a result of a decrease in neurological sequelae from GBS caused meningitis. Thus the resultant net cost of
the intervention is only around 134,000 NIS. Culture based screening will reduce the burden of disease by 12.6
discounted Quality Adjusted Life Years (QALYS), giving a very cost effective baseline incremental cost per QALY
(cf. risk factor screening) of 10,641 NIS per QALY. The data was very sensitive to rates of anaphylactic shock and
changes in the percentage of meningitis cases that had associated long term-sequelae.
Conclusion: It is recommended that Israel adopt universal culture-based GBS screening.
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Group B streptococcal (GBS) disease is a significant
cause of neonatal sepsis and early neonatal mortality
within the first week of life [early onset neonatal (EON)
diseases]. Intra-partum antibiotic prophylaxis (IAP) has
been documented to lower the incidence of EON GBS dis-
ease. The current practice in Israel is to perform culture
screenings for GBS in mothers according to the presence
of risk factors (e.g. pre-labor membrane rupture, preterm* Correspondence: gary.ginsberg@moh.health.gov.il
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reproduction in any medium, provided the orlabor, intra-partum fever). Women with identified risk
factors are then treated with antibiotics (IAP).
Consideration is now being given to implement a pro-
gram for universal screening of pregnant women in
Israel using a vaginal-anal culture taken at 35–37 weeks
of gestation. Mothers-to-be found with a positive culture
test would then receive IAP. Our model assumes that
the culture will be taken by a physician/nurse at
35–37 weeks gestation. This timing is current practice
and avoids the possibility of lower positive predictive
values that might occur in self-administered cultures or
cultures taken taken before 35 weeks gestation.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to whether or not to adopt this new intervention strat-
egy, this study will carry out a cost-utility analysis based
on calculating the cost per Quality Adjusted Life Year
(QALY) of implementing a universal screening strategy
for GBS in Israel.Methods
GBS colonization rates of 14.96% were based on
weighted ethnic specific colonization rates (n= 1,329)
from two recent Israeli studies [1,2]. Based on data from
the Israel Center for Disease Control and the Ministry of
Health, the incidence rate of early onset GBS in 2005-
2006 in Israel was 0.315 per 1000 births and 0.253 per
1000 births in 2008-9.
Assuming sensitivity and specificities for culture
screening of 0.95 and 0.97 respectively [3], we back-
calculated, the underlying natural incidence (null scenario)
of early onset GBS, under the baseline assumption in
2008-2009, that 15% of the mothers-to-be nationwide
received culture screening on an opportunistic basis (see
Appendix 1 for full details).
Finally we estimated the incidence in a future inter-
vention scenario where 85% of mothers-to-be would
receive culture screening, a figure currently attained in
the USA (3). Of the 15% who will not be screened, around
half were unscreened due to pre-term births [4].
We assumed that mothers who were given a scheduled
C-section birth would not receive IAP. Currently 18.9% of
Israeli births [4,5] are delivered by C-section of which 30%
are scheduled in advance and so would not receive IAP.
Based on evidence from a Cochrane meta-analysis [6],
we assumed that IAP with penicillin would prevent 83%
of the true positive identified cases from giving birth to
a child infected with GBS. We assumed that 0.022% of
the mothers who received IAP would develop an ana-
phylactic reaction [7], with an attendant case fatality rate
(CFR) of 10% [8].
In 2010, there were 166,184 live births (including
3,784 twins and 77 other multiple births) and 501 still
births, resulting from 162,740 deliveries in Israel [9]. By
multiplying the birth rate by the GBS incidence rate and
adjusting for the efficacy of the intervention, we
calculated the number of infants born with GBS in the
following three scenarios: the null scenario, the present
scenario and the future intervention scenario, where
85% of mothers to be would be culture-screened at
35–37 weeks.
Ninety percent of the children with EON GBS, were
assumed to suffer from only sepsis, whilst the remaining
10% had meningitis in addition to the sepsis, based
on the past ten years experience of the Shaare Zedek
Hospital in Jerusalem.The reported range of the percentage of meningitis
cases that develop long term neurological sequelae
increased from 28.4% (n=218) in studies from 1973-1985
[10-17] to 47.5% (n=141) in studies reported from 2000-
2012 [18,19]. As no studies were identified during the
period 1986-1999, the baseline estimates used in our
model were based on the 47.5% figure from the two
recent studies from the 21st century [18,19]. In addition,
we conducted a sensitivity analysis over a range of values
suggested by the literature.
The neurological sequelae consisted of severe (31.3%
of all neurological sequellae), moderate (33.4%) and mild
(35.3%) neurological disorders [18,19]. In addition a fur-
ther 4.6% of meningitis cases suffered from severe or
profound bilateral hearing loss [13].Costs of intervention
No additional marginal costs were imputed for the tak-
ing of the culture as this was considered to be part of
the routine examination of the mother-to-be. Laboratory
costs of analyzing the culture test (including the culture
tube) were 25.62 NIS per test. No provision was made
for physician labour time as this was considered to be
part of the routine pre-natal check-up in Israel.
Penicillin costs were based on an average of two doses
(given four hours apart) per birth (average delivery time
6–8 hours) of 5 million units of benzyl penicillin costing
11 NIS per 10mu vial (Personal Communication: Alan
Greenberg, Chief Pharmacist, Shaare Zedek Hospital,
Jerusalem).
No extra marginal cost was incurred for nurses time
in setting up the IV drip.Costs of anaphylactic shock, GBS cases and sequelae
Each fatal anaphylactic shock case was assumed to cost
one day's stay in an Intensive Care Unit (5,142 NIS).
Non-Fatal anaphylactic cases were assumed to spend an
extra two days in hospital [20] costing 4,208 NIS.
Hospital costs (in relation to non-GBS births) of
29.458 NIS and 37,872 NIS for GBS sepsis and sepsis
with meningitis cases were based on 14 and 18 days stay
respectively (obtained from an analysis of the case-notes
of 24 infants hospitalized for GBS in Shaare Zedek
Hospital, Jerusalem) in a quasi- Intensive Care Unit
(ICU) at 2,106 NIS per day (Ministry of Health, Price
List 2010). Fatal cases were assumed to cost the equiva-
lent of one days stay (5,142 NIS) in an ICU.
Post hospital care (e.g. outpatient follow up visits) was
assumed to amount to 36.0% of in-hospital care costs [21].
Both in- and post-hospital costs for GBS children were
adjusted by factors of 38.8% and 21.0% respectively in
order to estimate the additional costs for GBS children
compared with births to children without GBS [21].
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expected number of cases by the unit costs of health
services received. For chronic sequelae (deafness, and
brain damage), the expected age-specific number of
cases was multiplied by the age-specific discounted life-
time costs.
Costs of treating long-term sequelae were based on life-
time costs discounted at 3% per annum. Data on costs of
deafness were retrieved from a recent cost-utility analyis
of cochlear inplantsa. These costs included cost of aids or
implants, hearing tests, ear moulds, special therapy, school
visits, acoustic classrooms, amplification for teachers,
remedial education for children with and without cogni-
tive complications.
Lifetime costs were estimated to be around 2,640,519
NIS, 1,281,790 NIS and 316,180 NIS respectively for
severe, moderate and mild neurological brain damageb.
These costs included initial diagnostics and care costs,
care costs in subsequent years, additional medical costs
and special education costs.
Age-specific lifetime costs of caring for brain damage
(diagnosis, medical care, special education, rehabilitative
day care, residential care) were obtained from the minis-
try of healtha,b [22] and the ministry of social affairsc.
Around 75% and 5% of severe and moderate-mild
brain damaged persons were assumed to be cared for in
residential care centers, reflecting the trend of de-
institutionalisation [23] at a cost of around 105,000 NIS
per year.
Since the analysis was from a social perspective, esti-
mates of lost productivity due to sequelae were included
and based on the assumption that persons with moder-
ate or severe sequelae did not participate in the work-
force. Hearing challenged persons and persons with mild
sequelae were assumed to participate fully in the labor
force. Average discounted lifetime employment costs of
1,102,287 NIS per person were calculated from national
average gross wages [9] increased by a factor of 15%
to include employers pension, national insurance and
educational fund contributions and by age-specific
unemployment rates [9].
QALYS gained
QALY losses due to morbidity of GBS caused sepsis and
sepsis-meningitis cases were calculated by multiplying
the expected number of cases by the expected duration
of the illness (14 days and 18 days respectively), and the
disability weights of 0.31 [24] and 0.62 [25] respectively
attached to acute illness and the age-specific average
QALY weight of an infant not affected by GBS sepsis or
meningitisa.
QALY losses due to morbidity from chronic sequelae
from meningitis were calculated by multiplying the
expected number of sequelae by the average lifelongdisability weight of 0.964 [26-28] attached to the seque-
lae and the age-specific average QALY weight of a per-
son not affected by GBS meningitis [25]. The results
were discounted at a rate of 3% per annum over the per-
sons remaining life expectancy [9].
QALY losses due to morbidity from anaphylactic
reactions were based on an assumed disability weight for
meningitis (0.61) and the average duration of acute reac-
tion was assumed to be one day.
QALY losses due to mortality were estimated from the
product of the following:
– the number of incident cases
– case-fatality rate of 2.8% representing the excess
mortality in GBS as opposed to non-GBS cases
[29,30] or the 10% case fatality rate from
anaphalactic reactions [8].
– age and gender specific life expectancies at birth of
80.2 for males and 82.1 for females [9] in Israel,
– age-specific QALY weights of a healthy persona.
Cost-utility analysis
A spreadsheet model was built incorporating technical,
epidemiological, health service utilization and costs,
demographic and economic data described above.
The cost utility ratio calculated the net costs per Qual-
ity Adjusted Life Year (QALY) added of the intervention
of universal screening followed by IAP prophylactics,
using the formula.
Net Costs per QALY ¼
Costs of intervention
–Savings in treating GBS
QALYs added from averted
mortality and morbidity
All costs are at presented in mid-2010 price levels, at
the average annual exchange rate of 3.588 shekels to the
US dollar [9]. Costs are viewed from a societal perspec-
tive (i.e. including estimates of lost productivity in
addition to health and welfare services costs).
Estimates of QALYs added by the intervention do not
include those arising from reduced caregiver burden for
sequelae since such data is not available. All future costs
and QALYS were discounted at an annual rate of 3%.
Taking into account the resources available in Israel,
an intervention is defined as being very cost-effective
and cost-effective if the cost per QALY is less than the
per capita GNP of 106,548 NIS in 2010 [9] or between
1–3 times the per capita GNP (106,548-319,644 NIS)
respectively. If the cost per QALY is more than three
times the GNP per capita (319,644 NIS) then the inter-
vention is regarded as not being cost-effective [31].
Averted QALY losses are calculated by summing the
mortality and morbidity gains from decreased incidence
of GBS as a result of the universal screening intervention.
Table 1 Savings (vs. null scenario) as a result of
implementing universal screening for GBS (NIS at 2010
price levels)
TREATMENT COSTS Marginal Risk-factor Universal Savings





Fatality vs. non-GBS 1,997 2,347 968









Deafness 508,260 104,858 43,227
Severe Neuro 2,640,519 1,604,008 662,002
Moderate Neuro 1,281,790 828,425 341,906








Total Societal Costs 4,711,077 1,963,713 2,747,365
Table 2 Summary of costs (NIS at 2010 price levels) and




Screening Costs 617,408 3,498,644 2,881,236
Treatment Savings –614,683 –2,550,420 –1,935,737
lifetime productivity gains –256,990 –1,068,618 –811,628
Net Cost to Society –254,266 –120,394 133,872
Mortality QALYs lost 34.97 23.87 –11.10
Morbidity QALYs lost 0.56 0.24 –0.32
Sequellae QALYs lost 1.97 0.81 –1.16
Total QALYS lost 37.50 24.92 –12.58
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The intervention of universal screening (compared with
the current scenario) would increase screening costs
from 578,000 NIS to 3,278,000 million NIS. In addition,
the intervention would also increase penicillin costs
from 39,000 NIS to 221,000 NIS. The gross annual cost
of the intervention is therefore 3,499,000 million NIS
compared with 617,000 NIS under the current scenario,
an increase of 2,881,000 NIS.
The estimated natural incidence in Israel (i.e. in the
null-scenario of absence of any culture screening) is 0.30
per 1000 births resulting in 49.8 GBS births. As a result
of the estimated increase in culture screening to around
15% in 2008-9, there was a decrease in GBS incidence to
0.2525 per 1000 births in 2008-2009 (42.0 GBS births).
With the expansion of culture screening 85% of mothers
to be, the incidence rate will fall to 0.10 per 1000 births
(17.3 GBS births).
There will be around 24.7 fewer GBS births as a result
of universal screening. Treatment costs will decrease by
1,936,000 NIS (Table 1), of which 83.5% (1,620,000 NIS)
is attributable to decreased costs of long-term sequelae.
In addition, there will be gains of 812,000 NIS in work
productivity as a result of a decrease in medium and
severe neurological cases from 1.25 to 0.52 persons,
resulting in the intervention saving a total of 2,747,000
NIS (after rounding).
On account of the savings in treatment and care costs
and the productivity gains due to the decrease in the
number of GBS sequelae, the marginal incremental costs
of Universal GBS screening falls from 2,881,000 NIS to
only 134,000 NIS (Table 2).
In the current scenario, 37.5 QALYS are lost annually
due to GBS. Adopting universal screening will reduce
this burden to 24.9 QALYS, a gain of 12.6 (discounted)
QALYS (Table 2). Therefore, the baseline incremental
cost per QALY (cf the current scenario) is a very cost-
effective 10,641 NIS (133,872/12.58).
Net costs to society and health services per case of
GBS prevented are 5,432 NIS and 38,367 NIS, while net
costs per neurological sequelae case prevented is
117,616 NIS and 830,696 respectively.
Sensitivity analyses
Our calculations assumed sensitivity and specificity of
culture screening that were based on the use of an
enrichment broth that improves detection [3], which is
currently routinely used in Israel. Using a lower sensitiv-
ity rate of 0.87 and specificity of 0.96 [32] will increase
the cost (373,482 NIS) per QALY (10.85) ratio to 34,426
NIS per QALY.
Due to the linear structure of the underlying model,
the data was totally insensitive to changes in the current
percentage of persons being screened using cultures.The same value of 10,641 NIS per QALY applied even
when the assumed culture screening rate in 2008-9 was
only 10% or if it was 23% (i.e. the Maccabi health
services data applied to the whole population).
However the data was sensitive to changes in the per-
centage of meningitis cases that had long term-sequelae
as well as the incidence rate of anaphylactic shock
(Table 3). If the meningitis sequelae rate were to be
Table 3 Cost per QALY from societal perspective
% getting % of meningitis cases with long-term
sequelae
Anaphalaxis From IAP 22.5% 35% 47.5%* 60%
0% 68,536 36,609 5,558 cs
0.001% 69,883 37,336 5,749 cs
0.004% 74,252 39,690 6,155 cs
0.022%* 117,993 63,025 10,641 cs
0.040% 279,253 145,536 25,857 cs
* baseline rate.
cs denotes cost-saving.
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rendering the intervention to being cost-effective. If the
rate of anaphylactic shock rate were to be 0.001% [8,33]
or zero, the cost per QALY ratio will fall to 5,749 or
5,558 respectively. The data was also sensitive to changes
in GBS carrier prevalence rates as shown in relation to
meningitis sequelae rates in Table 4.Discussion
The estimated cost per QALY of 10,641 NIS is very-cost
effective according to the WHO criteria putting it on a
par with other various public health, preventive and
curative interventions in Israel. Investment of an add-
itional 2.9 million NIS of resources will in effect only
cost around 134,000 million NIS in the long-term. Even
using less sensitive direct agar plating [3], resulted in a
cost per QALY ratio that was still very cost-effective,
costing less than 32% of GNP per head.
Our finding that the marginal impact of expanding the
culture screening intervention (from 10% to 85%) was
very cost-effective was in keeping with results found
with different models in other countries. A UK study
found various culture testing interventions to be cost-
saving relative to a no intervention strategy [34]. A
Dutch study [35] found a combined screening and risk-
based study to be very cost-effective, while for screening
alone the cost per QALY was around twice the GNP per
head, rendering it just cost-effective. In addition, a recent
USA article suggests that universal treatment of term
pregnancies with a prior history of GBS colonization isTable 4 Cost per QALY from societal perspective
GBS carrier % of meningitis cases with long-term sequelae
Prevalence 22.5% 35% 47.5% 60%
0.2000 222,459 152,325 86,209 24,031
0.2525* 117,993 63,072 10,641 cs
0.3000 71,705 23,138 cs cs
* baseline rate.
cs denotes cost-saving.more cost-effective than a strategy of screening and
treating based on positive culture results [36].
Our model used a compliance rate of 85% based on
the US experience [3] and the fact that Israel has a well-
developed and efficient public health service which
reaches a much higher proportion of society than in
countries such as the US. In addition in the US many
women do not have full health insurance coverage as
opposed to Israel where there is universal health cover-
age. In any case, if a lower (or even higher) compliance
rate is achieved, this will not alter the cost-utility ratios
as both the cost numerator and QALY denominator will
be affected in the same proportions.
The use of intrapartum Polymerase Chain Reaction
(PCR) and optical immunoassay (OIA) screening
methods were not investigated in this paper because the
relatively high costs of these tests have resulted in them
being totally dominated in a recent British Cost-Utility
analysis [37] by the cheaper and more effective culture
test followed by IAP intervention scenario. However
despite its current high cost per QALY, PCR could in
the future offer benefits when used in the delivery room.
While this could provide a useful complementary
adjunct to universal screening, it does not offer the po-
tential to be a substitute for culture-based screening.
Costs per QALY for IAP are overestimated to the
extent that
– we were unable to estimate transport costs to
receive treatment and out-of-pocket expenses for
sequelae.
– we did not include any long-term sequelae from
sepsis cases without meningitis [38]
– we did not include the marginal savings in
physicians time (approximately 7 NIS per mother-
to-be) in order to identify and record risk factors
that would indicate GBS screening is required, since
use of these factors will not be required.
The colonization rate used in our model was 14.96%
[1,2]. This is of similar magnitude as rates reported each
year by the Shaare Zedek Medical Center in Jerusalem
and the rate of 16.9% based on the results of over 60,000
screening cultures taken by Maccabi Health Services (the
second largest HMO in Israel) from 2004-2011. [39-43].
The Maccabi data was not used as the membership of this
Health Service tends to have a higher socio-economic
profile than the country as a whole.
Our results were very sensitive to the percentage of
meningitis cases that have long-term sequelae. However
even the incidence of long-term sequelae would have to
fall below 25.05% to downgrade the intervention from
being very cost-effective to just cost-effective. If however,
long-term sequelae rates were to rise above 50.1% then
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averted of treating the sequelae outweigh the interven-
tion costs.
If the severity mix of sequelae was less severe (e.g. the
ratio of severe to mild cases decreases), then due to the
large differences in lifetime costs per case, the costs per
QALY of the intervention would rise.
Our analysis assumed that all mothers who were
culture positive would be given IPA in Israel where there
is universal national health insurance and good accessi-
bility to both pre-natal and curative health services.
Current experience in Israel points to 100% compliance
for those mothers-to-be who are currently culture
tested. This 100% compliance rate is also used in ana-
lyses carried out in the UK National Health Services [44]
and compares favorably with the USA where due to dif-
ferent health system structures, only around 80% of
mothers with an indication for IAP actually received it
appropriately [44].
Opponents to the introduction of universal screening
for GBS bring up the specter of increased development
of drug resistant GBS strains as well as other bacteria
that will become resistant to penicillin. However, in ac-
tuality according to CDC guidelines, the advent of uni-
versal screening in the states has NOT been associated
with increased resistant organisms [45].
In the US, under universal screening a greater than
expected number of cases of early onset GBS occurred
among infants born to women with negative prenatal
screening results. This phenomena of false negatives may
have been caused by a variety of local factors including the
culturing technique, the use of recommended transport
medium, and the laboratory culture protocol [46] and we
believe would be less likely to occur in Israel due to its
universal health coverage and more extensive public
health network of ante-natal clinics.
Conclusion
In summary, on the basis of the cost-utility analysis, that
integrates epidemiological, clinical and economic data, it is
recommended that Israel adopt universal GBS screening.
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Appendix I: estimation of natural and projected
GBS rates
The natural incidence rate of GBS (R0) is the rate that
would have occurred in the absence of any screening
program or IAP usage is calculated using the following
formulae:
RND15 ¼ R15= 100% C%ð Þ
R0 ¼ RND15þ RND15  S15 S0ð Þ  SEN
 EFF
Similarly, the expected rate of GBS (R85) if 85% of
mothers-to-be are screened in a nationwide program will
be:
R85 ¼ RND15þ RND15  S85 S15ð Þ  SEN
 EFF
Where
SEN = Sensitivity of culture screening to discover
GBS.
EFF = Efficacy of penicillin to prevent GBS.
R85 = Rate of GBS in all deliveries with culture
screening of 85% of mothers-to-be.
S85 = Screening rate of 85%
RND15 =Rate of GBS in all deliveries (excluding C-
sections known in advance) with culture screening of
15% of mothers-to-be.
R15 = Rate of GBS in all deliveries with culture
screening of 15% of mothers-to-be.
S15 = Screening rate of 15%
R0 = Rate of GBS in all deliveries with no culture
screening programme.
S0 = Screening rate of 0%
C = percentage of C-section births known in advance
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